These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22248134)

  • 41. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease.
    Hicks CW; Pandya MM; Itin I; Fernandez HH
    Parkinsonism Relat Disord; 2011 Jun; 17(5):379-81. PubMed ID: 21459656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Parkinson's disease].
    Yokochi M
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):5-14. PubMed ID: 10434578
    [No Abstract]   [Full Text] [Related]  

  • 43. [Levodopa dependency in Parkinson's disease: case report and review].
    Müller U; Reuter M; Hermann W; Gertz HJ
    Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of parkinsonism and legal capacity].
    Wallesch CW
    Fortschr Neurol Psychiatr; 2011 Aug; 79(8):441. PubMed ID: 21809256
    [No Abstract]   [Full Text] [Related]  

  • 45. Impulse control disorders and dopaminergic drugs.
    Morgan JC; Iyer SS; Sethi KD
    Arch Neurol; 2006 Feb; 63(2):298-9; author reply 299. PubMed ID: 16476826
    [No Abstract]   [Full Text] [Related]  

  • 46. Topiramate in managing impulse control disorders in Parkinson's disease.
    Bermejo PE
    Parkinsonism Relat Disord; 2008; 14(5):448-9. PubMed ID: 18339573
    [No Abstract]   [Full Text] [Related]  

  • 47. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathological gambling in Parkinson's disease: disease related or drug related?
    Calandrella D; Antonini A
    Expert Rev Neurother; 2011 Jun; 11(6):809-14. PubMed ID: 21651329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine dysregulation syndrome in Parkinson's disease: case report.
    Kummer A; Maia DP; Salgado JV; Cardoso FE; Teixeira AL
    Arq Neuropsiquiatr; 2006 Dec; 64(4):1019-22. PubMed ID: 17221016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances in pharmacological therapy of Parkinson's disease.
    Riederer P; Lange KW; Youdim MB
    Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
    Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
    Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-dependent impulse control disorders in piribedil overdose.
    Giugni JC; Tschopp L; Escalante V; Micheli F
    Clin Neuropharmacol; 2012; 35(1):49-50. PubMed ID: 22240861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases.
    Vitale C; Santangelo G; Erro R; Errico D; Manganelli F; Improta I; Moccia M; Barone P
    Parkinsonism Relat Disord; 2013 Apr; 19(4):483-4. PubMed ID: 23305965
    [No Abstract]   [Full Text] [Related]  

  • 54. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
    Tomer R; Aharon-Peretz J; Tsitrinbaum Z
    Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 56. Is pathological gambling in Parkinson's disease reduced by amantadine?
    Lee JY; Kim HJ; Jeon BS
    Ann Neurol; 2011 Jan; 69(1):213-4; author reply 214-5. PubMed ID: 21280095
    [No Abstract]   [Full Text] [Related]  

  • 57. [Hypersexuality during use of levodopa].
    van Deelen RA; Rommers MK; Eerenberg JG; Egberts AC
    Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2095-8. PubMed ID: 12448966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease.
    Fenu S; Wardas J; Morelli M
    Behav Pharmacol; 2009 Sep; 20(5-6):363-79. PubMed ID: 19724195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 60. Hypersexuality due to dopaminergic drugs.
    Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.